Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Methotrexate sodium
medac UK
L01BA01
Methotrexate sodium
100mg/1ml
Solution for infusion
Intraarterial; Intravenous; Intramuscular
No Controlled Drug Status
Valid as a prescribable product
BNF: 08010300; GTIN: 4037353017207
Methotrexate 100 mg/ml solution for injection Summary of Product Characteristics Updated 19-Jan-2022 | medac GmbH 1. Name of the medicinal product Methotrexate 100 mg/ml solution for injection WARNINGS The dose must be adjusted carefully depending on the body surface area if methotrexate is used for the treatment of tumour diseases. Fatal cases of intoxication have been reported after administration of incorrect calculated doses. Health care professionals and patients should be fully informed about risks of toxic effects. 2. Qualitative and quantitative composition concentration size amount per vial 100 mg methotrexate per ml (10.0 %) 10 ml 1,000 mg 100 mg methotrexate per ml (10.0 %) 50 ml 5,000 mg One vial with 10 ml contains 1,000 mg methotrexate. One vial with 50 ml contains 5,000 mg methotrexate. Excipient with known effect: sodium 3. Pharmaceutical form Solution for injection Clear orange-yellow solution 4. Clinical particulars 4.1 Therapeutic indications Methotrexate 100 mg/ml solution for injection may be used for the following indications: • Acute lymphocytic leukaemias (ALL) - in combination with other cytotoxic medicinal products • Non-Hodgkin's lymphomas - in combination with other cytotoxic medicinal products in adult patients with Non-Hodgkin's lymphomas of intermediate and high degree of malignancy - -in combination with other cytotoxic medicinal products in paediatric patients • Head and neck cancer - as palliative monotherapy in patients with metastatic or recurrent disease • Breast cancer - in combination with other cytotoxic medicinal products in patients for adjuvant treatment after tumour resection or mastectomy and for palliative treatment in advanced disease • Choriocarcinoma and similar trophoblastic diseases - as monotherapy in patients with good prognosis (low risk) - in combination with other cytotoxic medicinal products in patients with poor prognosis (high risk) • Osteosarcoma - in combination with other cytotoxic medicinal products for adjuvant and neoadjuvant therapy • Read the complete document